Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes

Journal of Virology

Volumn 88, Issue 15, 2014, Pages 8201-8212

  White, Elizabeth A ^a   Walther, Johanna ^b   Javanbakht, Hassan ^b   Howley, Peter M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PAPILLOMAVIRUS E6 PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; GENE INDUCTION; GENE TARGETING; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 17A; HUMAN PAPILLOMAVIRUS TYPE 20; HUMAN PAPILLOMAVIRUS TYPE 25; HUMAN PAPILLOMAVIRUS TYPE 38; HUMAN PAPILLOMAVIRUS TYPE 76; HUMAN PAPILLOMAVIRUS TYPE 8; HUMAN PAPILLOMAVIRUS TYPE 92; MDM2 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; P21 GENE; P53 GENE; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROAPOPTOTIC GENE; PROTEIN FUNCTION; TRANSACTIVATION; VIRUS GENE; WART VIRUS;

APOPTOSIS; BETAPAPILLOMAVIRUS; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; HOST-PATHOGEN INTERACTIONS; HUMANS; ONCOGENE PROTEINS, VIRAL; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTIONAL ACTIVATION;

EID: 84903903537     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01197-14     Document Type: Article

References (63)

1. Howley PM, Schiller JT, Lowy DR. 2013. Papillomaviruses, p 1662-1703. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott, Williams and Wilkins, Philadelphia, PA.
2. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79. http://dx.doi.org/10.1016/j.virol.2010.02.002.
3. Van Doorslaer K, Tan Q, Xirasagar S, Bandaru S, Gopalan V, Mohamoud Y, Huyen Y, McBride AA. 2013. The Papillomavirus Episteme: a central resource for papillomavirus sequence data and analysis. Nucleic Acids Res. 41:D571-D578. http://dx.doi.org/10.1093/nar/gks984.
4. Cardoso JC, Calonje E. 2011. Cutaneous manifestations of human papillomaviruses: a review. Acta Dermatovenerol. Alp. Panonica Adriat. 20: 145-154.
5. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. 1989. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8:3905-3910.
6. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:4417-4421.
7. Dyson N, Guida P, Munger K, Harlow E. 1992. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66:6893-6902.
8. Dyson N, Howley PM, Munger K, Harlow E. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937. http://dx.doi.org/10.1126/science.2537532.
9. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8:4099-4105.
10. Werness BA, Levine AJ, Howley PM. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79. http://dx.doi.org/10.1126/science.2157286.
11. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505. http://dx.doi.org/10.1016/0092-8674(93)90384-3.
12. Huibregtse JM, Scheffner M, Howley PM. 1993. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell. Biol. 13: 4918-4927.
13. White EA, Kramer RE, Tan MJ, Hayes SD, Harper JW, Howley PM. 2012. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J. Virol. 86:13174-13186. http://dx.doi.org/10.1128/JVI.02172-12.
14. Banuelos A, Reyes E, Ocadiz R, Alvarez E, Moreno M, Monroy A, Gariglio P. 2003. Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells. J. Pharmacol. Exp. Ther. 306:671-680. http://dx.doi.org/10.1124/jpet.103.051557.
15. Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullmann A, Hoppe-Seyler F. 1995. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10:927-936.
16. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, Peet CR, Lorenz LD, Nickel KP, Klingelhutz AJ, Lambert PF, Harari PM. 2013. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 73:4791-4800. http://dx.doi.org/10.1158/0008-5472.CAN-13-0587.
17. Patel D, Huang SM, Baglia LA, McCance DJ. 1999. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18:5061-5072. http://dx.doi.org/10.1093/emboj/18.18.5061.
18. Thomas MC, Chiang CM. 2005. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol. Cell 17:251-264. http://dx.doi.org/10.1016/j.molcel.2004.12.016.
19. Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ. 1999. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73:6209-6219.
20. Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R. 2013. The MDM2-p53 pathway revisited. J. Biomed. Res. 27:254-271.
21. Akgul B, Cooke JC, Storey A. 2006. HPV-associated skin disease. J. Pathol. 208:165-175. http://dx.doi.org/10.1002/path.1893.
22. Aldabagh B, Angeles JG, Cardones AR, Arron ST. 2013. Cutaneous squamous cell carcinoma and human papillomavirus: is there an association? Dermatol. Surg. 39:1-23. http://dx.doi.org/10.1111/j.1524-4725.2012.02558.x.
23. Feltkamp MC, de Koning MN, Bavinck JN, Ter Schegget J. 2008. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J. Clin. Virol. 43:353-360. http://dx.doi.org/10.1016/j.jcv.2008.09.009.
24. Pfister H. 2003. Chapter 8: Human papillomavirus and skin cancer. J. Natl. Cancer Inst. Monogr. 2003:52-56. http://dx.doi.org/10.1093/oxfordjournals.jncimonographs.a003483.
25. Dubina M, Goldenberg G. 2009. Viral-associated nonmelanoma skin cancers: a review. Am. J. Dermatopathol. 31:561-573. http://dx.doi.org/10.1097/DAD.0b013e3181a58234.
26. Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. 2011. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J. Investig. Dermatol. 131:1745-1753. http://dx.doi.org/10.1038/jid.2011.91.
27. Ganzenmueller T, Yakushko Y, Kluba J, Henke-Gendo C, Gutzmer R, Schulz TF. 2012. Next-generation sequencing fails to identify human virus sequences in cutaneous squamous cell carcinoma. Int. J. Cancer 131:E1173-E1179. http://dx.doi.org/10.1002/ijc.27581.
28. Jackson S, Harwood C, Thomas M, Banks L, Storey A. 2000. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev. 14:3065-3073. http://dx.doi.org/10.1101/gad.182100.
29. Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA. 2008. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J. Virol. 82:10408-10417. http://dx.doi.org/10.1128/JVI.00902-08.
30. Giampieri S, Storey A. 2004. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br. J. Cancer 90:2203-2209.
31. Wallace NA, Robinson K, Howie HL, Galloway DA. 2012. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB in-duced DNA damage. PLoS Pathog. 8:e1002807. http://dx.doi.org/10.1371/journal.ppat.1002807.
32. Cornet I, Bouvard V, Campo MS, Thomas M, Banks L, Gissmann L, Lamartine J, Sylla BS, Accardi R, Tommasino M. 2012. Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J. Virol. 86:2366-2370. http://dx.doi.org/10.1128/JVI.06579-11.
33. Massimi P, Thomas M, Bouvard V, Ruberto I, Campo MS, Tommasino M, Banks L. 2008. Comparative transforming potential of different human papillomaviruses associated with non-melanoma skin cancer. Virology 371:374-379. http://dx.doi.org/10.1016/j.virol.2007.10.015.
34. Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, Gabet AS, Sylla BS, Gissmann L, Hainaut P, Tommasino M. 2006. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep. 7:334-340. http://dx.doi.org/10.1038/sj.embor.7400615.
35. Caldeira S, Filotico R, Accardi R, Zehbe I, Franceschi S, Tommasino M. 2004. p53 mutations are common in human papillomavirus type 38-positive non-melanoma skin cancers. Cancer Lett. 209:119-124. http://dx.doi.org/10.1016/j.canlet.2003.12.003.
36. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, Giarre M, de Villiers EM, Filotico R, Boukamp P, Tommasino M. 2003. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J. Virol. 77:2195-2206. http://dx.doi.org/10.1128/JVI.77.3.2195-2206.2003.
37. Muschik D, Braspenning-Wesch I, Stockfleth E, Rosl F, Hofmann TG, Nindl I. 2011. Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PLoS One 6:e27655. http://dx.doi.org/10.1371/journal.pone.0027655.
38. Lane DP, Crawford LV. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263. http://dx.doi.org/10.1038/278261a0.
39. Linzer DI, Levine AJ. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52. http://dx.doi.org/10.1016/0092-8674(79)90293-9.
40. Sarnow P, Ho YS, Williams J, Levine AJ. 1982. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387-394. http://dx.doi.org/10.1016/0092-8674(82)90356-7.
41. Zantema A, Schrier PI, Davis-Olivier A, van Laar T, Vaessen RTMJ, van der Eb AJ. 1985. Adenovirus serotype determines association and localization of the large E1B tumor antigen with cellular tumor antigen p53 in transformed cells. Mol. Cell. Biol. 5:3084-3091.
42. Sato Y, Tsurumi T. 2013. Genome guardian p53 and viral infections. Rev. Med. Virol. 23:213-220. http://dx.doi.org/10.1002/rmv.1738.
43. White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, Munger K, Harper JW, Howley PM. 2012. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc. Natl. Acad. Sci. U.S.A. 109:E260-E267. http://dx.doi.org/10.1073/pnas.1116776109.
44. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG. 2000. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol. 20:1436-1447. http://dx.doi.org/10.1128/MCB.20.4.1436-1447.2000.
45. Degen M, Natarajan E, Barron P, Widlund HR, Rheinwald JG. 2012. MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin gamma2 expression in oral dysplasia and squamous cell carcinoma. Am. J. Pathol. 180:2462-2478. http://dx.doi.org/10.1016/j.ajpath.2012.02.028.
46. Wei W, Barron PD, Rheinwald JG. 2010. Modulation of TGF-betainducible hypermotility by EGF and other factors in human prostate epithelial cells and keratinocytes. In Vitro Cell Dev. Biol. Anim. 46:841-855. http://dx.doi.org/10.1007/s11626-010-9353-8.
47. White EA, Clark CL, Sanchez V, Spector DH. 2004. Small internal deletions in the human cytomegalovirus IE2 gene result in nonviable recombinant viruses with differential defects in viral gene expression. J. Virol. 78:1817-1830. http://dx.doi.org/10.1128/JVI.78.4.1817-1830.2004.
48. Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207-210. http://dx.doi.org/10.1093/nar/30.1.207.
49. Tomasz M, Palom Y. 1997. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol. Ther. 76:73-87. http://dx.doi.org/10.1016/S0163-7258(97)00088-0.
50. Butz K, Geisen C, Ullmann A, Spitkovsky D, Hoppe-Seyler F. 1996. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int. J. Cancer 68:506-513. http://dx.doi.org/10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2.
51. Shieh SY, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334. http://dx.doi.org/10.1016/S0092-8674(00)80416-X.
52. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP. 2001. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20:1331-1340. http://dx.doi.org/10.1093/emboj/20.6.1331.
53. Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G. 1996. Mutation of phosphoserine 389 affects p53 function in vivo. J. Biol. Chem. 271:29380-29385. http://dx.doi.org/10.1074/jbc.271.46.29380.
54. Ullrich SJ, Sakaguchi K, Lees-Miller SP, Fiscella M, Mercer WE, Anderson CW, Appella E. 1993. Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wildtype p53. Proc. Natl. Acad. Sci. U.S.A. 90:5954-5958. http://dx.doi.org/10.1073/pnas.90.13.5954.
55. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245. http://dx.doi.org/10.1016/0092-8674(92)90644-R.
56. Bendjennat M, Boulaire J, Jascur T, Brickner H, Barbier V, Sarasin A, Fotedar A, Fotedar R. 2003. UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell 114:599-610. http://dx.doi.org/10.1016/j.cell.2003.08.001.
57. Carvajal LA, Manfredi JJ. 2013. Another fork in the road-life or death decisions by the tumour suppressor p53. EMBO Rep. 14:414-421. http://dx.doi.org/10.1038/embor.2013.25.
58. Jackson S, Storey A. 2000. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 19:592-598. http://dx.doi.org/10.1038/sj.onc.1203339.
59. Wallace NA, Robinson K, Galloway DA. 2014. Beta human papillomavirus E6 expression inhibits p53 stabilization and increases tolerance of genomic instability. J. Virol. 88:6112-6127. http://dx.doi.org/10.1128/JVI.03808-13.
60. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN. 2011. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333:1154-1157. http://dx.doi.org/10.1126/science.1206923.
61. Brimer N, Lyons C, Wallberg AE, Vande Pol SB. 2012. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling. Oncogene 31:4639-4646. http://dx.doi.org/10.1038/onc.2011.589.
62. Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M, Dricot A, Askenazi M, Tavares M, Pevzner SJ, Abderazzaq F, Byrdsong D, Carvunis AR, Chen AA, Cheng J, Correll M, Duarte M, Fan C, Feltkamp MC, Ficarro SB, Franchi R, Garg BK, Gulbahce N, Hao T, Holthaus AM, James R, Korkhin A, Litovchick L, Mar JC, Pak TR, Rabello S, Rubio R, Shen Y, Singh S, Spangle JM, Tasan M, Wanamaker S, Webber JT, Roecklein-Canfield J, Johannsen E, Barabasi AL, Beroukhim R, Kieff E, Cusick ME, Hill DE, Munger K, Marto JA, Quackenbush J, Roth FP, DeCaprio JA, Vidal M. 2012. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 487:491-495. http://dx.doi.org/10.1038/nature11288.
63. Tan MJ, White EA, Sowa ME, Harper JW, Aster JC, Howley PM. 2012. Cutaneous beta-human papillomavirus E6 proteins bind Mastermindlike coactivators and repress Notch signaling. Proc. Natl. Acad. Sci. U.S.A. 109:E1473-E1480. http://dx.doi.org/10.1073/pnas.1205991109.